Macuject
Bradley Beddoes currently serves as the Chief Technology Officer at Macuject since November 2021. Prior to this role, Bradley held various positions at Australian Access Federation Ltd (AAF) from October 2009 to September 2021, including Head of Technology and Technical Lead. Bradley founded and led Intient Pty Ltd, a tech startup based in Queensland, from January 2008 to October 2009. Earlier in their career, Bradley worked as a Senior Programmer at Queensland University of Technology from January 2003 to January 2008. Bradley earned a degree in Information Technology with a focus on Computer Software Engineering from Southern Cross University between 2000 and 2002. Areas of expertise include digital identity, authentication, and cyber security.
This person is not in any teams
Macuject
Macuject is a clinician-driven digital health company created to end preventable blindness for tens of millions across the globe, starting with age-related macular degeneration (AMD); diabetic retinopathy, cataract and glaucoma will follow. Our innovative clinical decision support software is specifically designed to address both wet and dry forms of AMD, empowering healthcare professionals to make accurate and timely diagnoses, optimise treatment plans, and monitor disease progression more effectively. By harnessing the power of cutting-edge artificial intelligence and integrating seamlessly with existing medical infrastructure, our SaaS solutions enable early intervention and personalized care, dramatically improving patient outcomes and significantly reducing the social and economic burden of these blinding conditions. Macuject’s founder-CEO is Dr. Devinder Chauhan, a prominent Melbourne retinal specialist responsible for 8% of his state's AMD treatments. Leveraging his expertise and network, he has brought together a talented team of professionals with diverse backgrounds in commercial, technical and clinical development. Our collaborative team is dedicated to developing, refining, and promoting our ground-breaking products, ensuring both their clinical relevance and market adoption.